The Incheon Free Economic Zone Authority, Hanlim Pharmaceutical, and Incheon Technopark (ITP) signed a business agreement on the 22nd to discover and nurture startups in the bio sector.
Under this agreement, the institutions plan to identify startups with technologies demanded by the industry and support product validation and commercialization.
Hanlim Pharmaceutical is a leading company specializing in hypertension, osteoporosis, and ophthalmic pharmaceuticals, ranking first domestically in ophthalmic pharmaceutical production capacity.
In June of last year, the company registered as an accelerator (startup planner) to focus on investing in and nurturing bio startups and promoting co-growth, participating in joint research and development for global pharmaceutical development as a strategic investor (SI).
In particular, after signing an investment agreement worth KRW 15 billion with Incheon Startup Park resident company RudaCure Inc., Hanlim Pharmaceutical has been actively supporting the development of RCI001, the dry eye disease treatment.